BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33391748)

  • 1. Renal outcomes of radioligand therapy: experience of
    Gallyamov M; Meyrick D; Barley J; Lenzo N
    Clin Kidney J; 2020 Dec; 13(6):1049-1055. PubMed ID: 33391748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Safety of [
    Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
    Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
    Widjaja L; Derlin T; Ross TL; Bengel FM; Werner RA
    Prostate; 2022 Jan; 82(1):86-96. PubMed ID: 34633090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
    Sathekge MM; Lawal IO; Bal C; Bruchertseifer F; Ballal S; Cardaci G; Davis C; Eiber M; Hekimsoy T; Knoesen O; Kratochwil C; Lenzo NP; Mahapane J; Maserumule LC; Mdlophane AH; Mokoala KMG; Ndlovu H; Pant V; Rathke H; Reed J; Sen IB; Singh A; Sood A; Tauber R; Thakral P; Yadav MP; Morgenstern A
    Lancet Oncol; 2024 Feb; 25(2):175-183. PubMed ID: 38218192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended therapy with [
    Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.
    Kesavan M; Meyrick D; Gallyamov M; Turner JH; Yeo S; Cardaci G; Lenzo NP
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33799431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Arm, Low-Dose, Prospective Study of
    Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
    J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Bu T; Zhang L; Yu F; Yao X; Wu W; Zhang P; Shi L; Zang S; Meng Q; Ni Y; Shao G; Qiu X; Ai S; Jia R; Guo H; Wang F
    Front Oncol; 2022; 12():835956. PubMed ID: 35402274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
    Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early molecular imaging response assessment based on determination of total viable tumor burden in [
    Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [
    Hartrampf PE; Seitz AK; Weinzierl FX; Serfling SE; Schirbel A; Rowe SP; Kübler H; Buck AK; Werner RA
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4262-4270. PubMed ID: 35650263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of [
    Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
    J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
    [No Abstract]   [Full Text] [Related]  

  • 19. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 20. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Almuradova E; Seyyar M; Arak H; Tamer F; Kefeli U; Koca S; Sen E; Telli TA; Karatas F; Gokmen I; Turhal NS; Sakalar T; Ayhan M; Ekinci F; Hafizoglu E; Kahraman S; Kesen O; Unal C; Alan O; Celik S; Yekeduz E; Omur O; Gokmen E
    Int J Cancer; 2024 Feb; 154(4):692-700. PubMed ID: 37818966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.